Sarcopenia-Pipeline Insights, 2017

DelveInsight’s, “Sarcopenia - Pipeline Insights, 2017”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall underSarcopenia. This report provides information on the therapeutic development for Sarcopeniadealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the company’s information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Introduction
Overview
Pipeline Therapeutics
Comparative Analysis
Late Stage Products (Phase III)
Mid Stage Products (Phase II)
Early Stage Products (Phase I)
Therapeutic Assessment- Active Products
Dormant Products
Discontinued Products
Companies Involved in Therapeutic Development
Appendix
Consulting Services
About DelveInsight
Contact Us
Disclaimer

List Of Tables

Table 1:Number of Products Under Development for Sarcopenia
Table 2: Number of Products under Development by Companies
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Discovery and Pre-clinical Stage Products
Table 7: Unknown Stage Products
Table 8: Assessment by Monotherapy Products
Table 9: Assessment by Combination Therapy Products
Table 10: Assessment by Route Of Administration
Table 11: Assessment by Stage and Route Of Administration
Table 12: Assessment by Molecule Type
Table 13: Assessment by Stage and Molecule Type
Table 14: Dormant Products
Table 15: Discontinued Products
Table 16: ARMGO Pharma, Overview
Table 17: Biophytis, Overview
Table Continued…..
Table 30:Regeneron Pharmaceuticals, Inc., Overview

List Of Figures

Figure 1: Number of Products under Development for Sarcopenia
Figure 2: Late Stage Products (Filed and Phase III)
Figure 3: Mid Stage Products (Phase II)
Figure 4: Early Stage Products (Phase I)
Figure 5: Pre-clinical Stage Products
Figure 6: Unknown Stage Products
Figure 7: Assessment by Monotherapy Products
Figure 8: Assessment by Combination Therapy Products
Figure 9: Assessment by Route of Administration
Figure 10: Assessment by Stage and Route of Administration
Figure 11: Assessment by Molecule Type
Figure 12: Assessment by Stage and Molecule Type
Figure 13: Dormant Products
Figure 14: Discontinued Products

Fill The Form For Sample Request

There is no Reviews available